You have 9 free searches left this month | for more free features.

Atezolizumab

Showing 751 - 765 of 765

STUDY
CONDITIONS
INTERVENTIONS
LOCATIONS

Colorectal Cancer Trial in Guangzhou (JS001, regorafenib tablet)

Unknown status
  • Colorectal Cancer
  • Guangzhou, Guangdong, China
    Sun Yat-sen University Cancer Center
May 11, 2020

Advanced Non-small Cell Lung Cancer With Malignant Pleural

Unknown status
  • Non-Small Cell Lung Cancer
  • Non-Intervention
  • (no location specified)
Feb 10, 2020

Immune CHeckpoint Inhibitors Monitoring of Adverse Drug ReAction

Completed
  • Arthritis
  • +7 more
  • Immune checkpoint inhibitor
  • Paris, France
    AP-HP, Pitié-Salpêtrière Hospital, Department of Pharmacology, C
Sep 24, 2019

Lung Tumor Malignant, Interstitial Lung Disease Trial in Warszawa (Prolonged glucocorticosteroid (prednisone) regimen, Short

Unknown status
  • Lung Neoplasm Malignant
  • Interstitial Lung Disease
  • Prolonged glucocorticosteroid (prednisone) regimen
  • Short glucocorticosteroid (prednisone) regimen
  • Warszawa, Mazowieckie, Poland
    Instutut Gruzlicy I Chorob Pluc
Feb 26, 2020

NSCLC Metastatic Trial in Seoul (Pembrolizumab plus chemo, Placebo plus chemo)

Unknown status
  • Non-small Cell Lung Cancer Metastatic
  • Pembrolizumab plus chemotherapy
  • Placebo plus chemotherapy
  • Seoul, Korea, Republic of
    Jong-Mu Sun
Dec 5, 2019

Inactivated Trivalent Influenza Vaccine on NSCLC Patients

Not yet recruiting
  • Non Small Cell Lung Cancer
  • Influenza Vaccine
  • PD-1/PD-L1 inhibitors
  • Inactivated trivalent influenza vaccine
  • Hong Kong, Hong Kong, China
  • +1 more
Apr 20, 2020

Metastatic Colorectal Cancer Trial in Guangzhou (Camrelizumab)

Unknown status
  • Metastatic Colorectal Cancer
  • Guangzhou, Guangdong, China
    Cancer center of Sun Yat-sen University
Apr 11, 2019

Testing Tumor Tissue and Blood to Help Select Personalized

Not yet recruiting
  • NSCLC
  • ctDNA, tumor NGS
  • (no location specified)
Mar 2, 2021

The Predicted Potential of Quantitative T Cell Repertoire(TCR)

Unknown status
  • Non-Small Cell Lung Cancer
  • Atezolizumab (MPDL3280A)
  • Hangzhou, Zhejiang, China
    The First Affiliated Hospital of College of Medicine, Zhejiang U
Jul 21, 2017

NSCLC Trial in Ann Arbor, Seattle (MPDL3280A, Hypofractionated Radiotherapy)

Completed
  • Non-small Cell Lung Cancer
  • Ann Arbor, Michigan
  • +1 more
Feb 7, 2019

Advanced or Metastatic Melanoma, Advanced or Metastatic NSCLC Trial in France (immune-checkpoint inhibitors therapies)

Unknown status
  • Advanced or Metastatic Melanoma
  • Advanced or Metastatic NSCLC
  • immune-checkpoint inhibitors therapies
  • Marseille, Bouches Du Rhône, France
  • +8 more
Sep 25, 2019

Tumor, Solid, Lymphoma Trial in Beijing (GR1405 injection)

Unknown status
  • Tumor, Solid
  • Lymphoma
  • GR1405 injection
  • Beijing, China
    Cancer Institute/Hospital, Chinese Academy of Medical Sciences &
Nov 4, 2018

Urothelial Carcinoma Trial in United States (Atezolizumab [TECENTRIQ])

Approved for marketing
  • Urothelial Carcinoma
  • Atezolizumab [TECENTRIQ]
  • Scottsdale, Arizona
  • +39 more
Nov 1, 2016

NSCLC Trial in New Haven (CDX-1401, MPDL3280A)

Withdrawn
  • Non-Small Cell Lung Cancer
  • New Haven, Connecticut
    Yale University
Jun 21, 2017

Cancer, Multiple Indications Trial in United States (Anti-PDL-1 antibody)

Completed
  • Cancer, Multiple Indications
  • Anti-PDL-1 antibody
  • Los Angeles, California
  • +10 more
Sep 3, 2015